Aberdeen Group plc and abrdn Inc. Reduce Stake in Quoin Pharmaceuticals to 4.16%

On April 29, 2026, Aberdeen Group plc and its subsidiary abrdn Inc. filed a Schedule 13G/A regarding their holdings in Quoin Pharmaceuticals, Ltd. (QNRX). The filing indicates that the reporting persons collectively hold 75,000 American Depositary Shares, representing a 4.16% ownership stake in the company. This filing serves as an amendment to a previous statement and highlights that the reporting entities now hold less than the 5% threshold typically requiring active disclosure. Specifically, Aberdeen Group plc acts as the parent holding company, while abrdn Inc. manages the shares on behalf of underlying clients. All reported shares are held with shared voting and dispositive power. The filing includes a certification that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Consequently, the filers have indicated they no longer beneficially own more than five percent of the class of securities.